Stocksigma LogoStocksigma Logo

Kabra Drugs Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh)

■ Revenue: 3,195 (+61.7% YoY | -30.9% QoQ) ■ EBITDA: 269 (+31.9% YoY | -3.6% QoQ) ■ EBITDA Margin (%): 8.4 (-190 bps YoY | +238 bps QoQ) ■ PAT: 192 (+4.6%

Kabra Drugs Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh)

Kabra Drugs Ltd · Financial Result · 07 Nov 2026, 12:46 am

Kabra Drugs Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh) ■ Revenue: 3,195 (+61.7% YoY | -30.9% QoQ) ■ EBITDA: 269 (+31.9% YoY | -3.6% QoQ) ■ EBITDA Margin (%): 8.4 (-190 bps YoY | +238 bps QoQ) ■ PAT: 192 (+4.6% YoY | -9.5% QoQ) ■ EPS (INR): 0.81 (+5.2% YoY | -10.0% QoQ)

Original exchange filing (PDF)

More announcements from Kabra Drugs Ltd

All Kabra Drugs Ltd announcements